SUPERGEN COMPLETES CONTRACT TO TRANSITION WYETH DISTRIBUTION OF NIPENT, OUTSIDE OF THE U.S.

SuperGen, Inc. today announced that a contract has been executed to terminate the distribution of Nipent (pentostatin for injection) by Wyeth and transition distribution to SuperGen, Inc. The Company paid Wyeth a $2.1 million dollar early termination fee, making it effective June 1, 2006. SuperGen and Wyeth will collaborate to ensure uninterrupted distribution services during the transition period. Distribution and marketing for Nipent in Europe will be managed by SuperGen's subsidiary, EuroGen Pharmaceuticals Limited, which is based in Cheltenham, United Kingdom.
PR Newswire